Lexeo Therapeutics (LXEO) Capital Leases (2022 - 2026)

Lexeo Therapeutics has reported Capital Leases for 5 years, with the latest figure at $198000.0 in Q1 2026.

• Quarterly Capital Leases fell 71.63% year-over-year to $198000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $198000.0 (down 71.63% YoY) and the FY2025 annual result came in at $327000.0, down 59.98% from the prior year.
• Capital Leases slipped to $198000.0 in Q1 2026 per LXEO's latest filing, from $327000.0 in the prior quarter.
• Over five years, Capital Leases peaked at $1.6 million in Q4 2022 and troughed at $198000.0 in Q1 2026.
• A 5-year average of $870333.3 and a median of $873500.0 in 2024 frame the typical range for Capital Leases.
• The sharpest annual moves came in 2023 and 2026: Capital Leases slipped 24.33% in 2023, then slumped 71.63% in 2026.
• Over 5 years, Capital Leases stood at $1.6 million in 2022, then dropped by 24.33% to $1.2 million in 2023, then plunged by 34.48% to $817000.0 in 2024, then plunged by 59.98% to $327000.0 in 2025, then slumped by 39.45% to $198000.0 in 2026.
• According to Business Quant data, Capital Leases over the past three periods registered $198000.0, $327000.0, and $454000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.